Advaxis (OTCMKTS:ADXS) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Advaxis (OTCMKTS:ADXSGet Rating) in a report released on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock.

Advaxis Price Performance

Advaxis stock opened at $2.41 on Friday. The firm has a 50 day simple moving average of $1.58 and a 200-day simple moving average of $1.71. The stock has a market capitalization of $4.38 million, a PE ratio of -0.27 and a beta of 2.15. Advaxis has a 12-month low of $1.00 and a 12-month high of $13.12.

About Advaxis

(Get Rating)

Advaxis, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer.

Further Reading

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.